Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk

15 Jan 2018

Abstract excerpt

Background: The role of normal tissue gene promoter methylation in cancer risk is poorly understood. Objective: To assess associations between normal tissue BRCA1 methylation and ovarian cancer risk. Design: 2 case-control (initial and validation) studies. Setting: 2 hospitals in Norway (patients) and a population-based study (control participants). Participants: 934 patients and 1698 control participants in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to Epigenetics and DNA Methylation
Share to Ovarian cancer diagnosis and treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29335712
DOI: 10.7326/m17-0101

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer RiskPMID 29335712Read ↗

Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian CancerSemantic proximity Read ↗

BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients – A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD)Semantic proximity Read ↗

The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancerSemantic proximity Read ↗

Peripheral blood DNA methylation detected in the BRCA1 or BRCA2 promoter for sporadic ovarian cancer patients and controls.Semantic proximity Read ↗

Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk.Semantic proximity Read ↗

DNA Methylation and Transcriptomic Features are Preserved Throughout Disease Recurrence and Chemoresistance in High Grade Serous Ovarian CancersSemantic proximity Read ↗

DNA methylation and transcriptomic features are preserved throughout disease recurrence and chemoresistance in high grade serous ovarian cancersSemantic proximity Read ↗

Constitutional BRCA1 and MGMT Methylation Are Significant Risk Factors for Triple-Negative Breast Cancer and High-Grade Serous Ovarian Cancer in Saudi Women.Semantic proximity Read ↗

Peripheral blood BRCA1 methylation profiling to predict familial ovarian cancer.Semantic proximity Read ↗

Methylomic Analysis of Ovarian Cancers Identifies Tumor-Specific Alterations Readily Detectable in Early Precursor LesionsSemantic proximity Read ↗

The Effects of BRCA1 and BRCA2 Promoter Methylation on Clinicopathological Characteristics and Clinical Outcomes in HGSOC.Semantic proximity Read ↗

Blood DNA methylation and breast cancer risk: a prospective nested case-control study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.